2. Sorafenib in Treating Patients With Soft Tissue Sarcomas
Alveolar Soft Part Sarcoma (ASPS) is highly angiogenic: it involves intensive growth of new blood vessels into the tumor. Those blood vessels connect the tumor to the blood system, supply oxygen and nutrients to the tumor, remove waste and enable dissemination of tumor cells into the body through this connection to the blood stream. Therefore, it is possible that the application of specific drugs, which may inhibit the creation of new blood vessels, is a way to combat ASPS.
Sorafenib (Nexavar) is designed to interfere with growth of new blood vessels and the growth of new cancer cells.
If you wish to participate in any of the Sorafenib (Nexavar) clinical trials, talk to your doctor and/or contact one of the medical centers across the USA, that are listed in the links above, to determine if those clinical trials are right for you.
Yosef Landesman, Ph.D.
President & Cancer Research Director
Cure Alveolar Soft Part Sarcoma International (iCureASPS)